Human chorionic gonadotropin in doping and its control. Strategy of the Havana Anti-doping Laboratory
Keywords:
human chorionic gonadotropin, immunoassay, sports, SUMAAbstract
Human chorionic gonadotropin (hCG) has been included in the List of Prohibited Substances for athletes since 1987, due to its ability to increase and stabilize the endogenous production of testosterone. The aims of this paper were to describe the justification for the use of the hormone for doping purposes, relate the main hormone detection tests with the standards established in the field of sports, and describe the strategy of the Havana Anti-Doping Laboratory (LAH), in the environment of current regulations.
The LAH analysis strategy is based on a prescreening assay using a national production technology such as the Ultra-Micro Analytical System (SUMA), for the detection of the total fraction of the hormone. The quantification of the intact fraction is carried out by means of an electro chemiluminescent assay with the use of the Elecsys Cobas e411 analyzer from the German firm Roche.
Downloads
Published
How to Cite
Issue
Section
License
The journal Anales de la Academia de Ciencias de Cuba protects copyright, and operates with a Creative Commons License 4.0 (Creative Commons Attribution-NonCommercial License 4.0). By publishing in it, authors allow themselves to copy, reproduce, distribute, publicly communicate their work and generate derivative works, as long as the original author is cited and acknowledged. They do not allow, however, the use of the original work for commercial or lucrative purposes.
The authors authorize the publication of their writings, retaining the authorship rights, and assigning and transferring to the magazine all the rights protected by the intellectual property laws that govern in Cuba, which imply editing to disseminate the work.
Authors may establish additional agreements for the non-exclusive distribution of the version of the work published in the journal (for example, placing it in an institutional repository or publishing it in a book), with recognition of having been first published in this journal.
To learn more, see https://creativecommons.org